VICTORIA, British Columbia, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc. (EHT) (TSXV:EMH) (OCTQX:EMHTF) today announced that its wholly owned subsidiary, Emerald Health Botanicals Inc., has completed a purchase of dried cannabis from Supreme Pharmaceuticals Inc.'s (Supreme) (TSXV:FIRE) subsidiary, 7ACRES.
"Emerald's strategy emphasizes value-added downstream product development. Our ability to source low-cost cannabis from our own facilities is increasing through our Pure Sunfarms joint venture, which presents industry-leading scale and cost potential. Partners such as Supreme will help us supplement our supply for the higher-end dried flower segment, both for current patients and for the anticipated growth in domestic and international demand for medical and adult-use cannabis," said Dr. Bin Huang, President and CEO of Emerald. "Supreme's 7ACRES is a high quality grower that meets our own standards for cultivation, and which we are pleased to work with to expand our sources of dried cannabis."
Join us on our journey of making lives better through cannabis science.
About Supreme Pharmaceuticals Inc.
Supreme Pharmaceuticals is committed to becoming a leading cultivator and distributor of sun-grown cannabis through its wholly owned subsidiary 7 Acres. 7 Acres is a federally licensed producer of medical cannabis pursuant to the ACMPR (access to cannabis for medical purposes regulations) operating inside a 342,000-square-foot hybrid greenhouse facility.
About Emerald Health Therapeutics Inc.
For investor and media contacts:
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statements Regarding Forward Looking Information
Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements".
We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
